Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALPN

Alpine Immune Sciences (ALPN) Stock Price, News & Analysis

Alpine Immune Sciences logo

About Alpine Immune Sciences Stock (NASDAQ:ALPN)

Advanced Chart

Key Stats

Today's Range
$64.97
$64.97
50-Day Range
$64.37
$64.97
52-Week Range
$8.33
$65.00
Volume
2 shs
Average Volume
1.92 million shs
Market Capitalization
$4.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Stock News Headlines

Alpine Immune Sciences Inc.
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences Inc
See More Headlines

ALPN Stock Analysis - Frequently Asked Questions

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.56. The biotechnology company had revenue of $8.52 million for the quarter, compared to the consensus estimate of $22.30 million. Alpine Immune Sciences had a negative net margin of 65.17% and a negative trailing twelve-month return on equity of 14.86%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpine Immune Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
11/09/2021
Today
5/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALPN
Employees
142
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$32.18 million
Pretax Margin
-64.99%

Debt

Sales & Book Value

Annual Sales
$56.52 million
Price / Cash Flow
N/A
Book Value
$4.85 per share
Price / Book
13.40

Miscellaneous

Free Float
39,581,000
Market Cap
$4.46 billion
Optionable
Optionable
Beta
0.97
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:ALPN) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners